Keywords
HLA
uveitis
How to Cite
Abstract
Background: Vogt-Koyanagi-Harada (VKH) syndrome is a severe disease with autoimmu- ne etiology. It manifests with bilateral panuveitis and can affect the nervous and auditory system, as well as the skin. The influence of genetic factors on the expression of VKH has been evidenced in multiple studies. It has a poor visual prognosis if diagnosis and treat- ment are delayed. Having biomarkers of genetic susceptibility could be of great help. The aim of this study is to describe the clinical spectrum and determine genetic biomarkers of susceptibility in VKH disease.
Methodology: Case-control study of genetic susceptibility for VKH. Clinical data was registered and HLA DRB1 genotyping of cases and controls was performed.
Results: 21 patients with VKH were included for the clinical registry, 16 of these were enrolled for HLA-DRB1 genotyping. Thirty two healthy controls were included. Most pa- tients were female (81%,) average age 35 years, the clinical forms were: Probable VKH 10 (47.6%) and Incomplete VKH 10 (47.6%), Complete VKH 1 case (4.7%).Genotyping: alleles of the HLA DRB1*02 group were present in 5 of the 16 patients (31%) (p0.004) and absent in the controls, no relationship with specific alleles was found. The most frequent allele was HLA DRB1*01:02 present in 4 (25%)of cases and absent in controls.
Conclusion: Most of the patients were young female adults. Probable and Incomplete forms were more common. Genetic association of VKH disease with alleles of the DRB1*02 group was found in this Paraguayan cohort. No statistically significant relationship was found with any specific allele, probably because the sample was small. The most frequent allele HLA DRB1*01:02 could be a candidate genetic biomarker in this population.
References
(1) Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes- garcia L, et al. Revised Diagnostic Criteria for. Am J Ophthalmol. 2001;131:647–52.
(2) Koyanagi V, Attia S, Khochtali S, Kahloun R, Zaouali S, Khairallah M, et al. Vogt – Koyanagi – Harada disease. 2014;9899.
(3) Jr ETC, Rathinam SR, Tugal-tutkun I, Muccioli C, Zierhut M, Cunningham ET, et al. Vogt-Koyanagi-Harada Disease Vogt- Koyanagi-Harada Disease. 2014;3948.
(4) Alâez C, Flores-a H, Elena L, Munguîa A, Rodrîguez A, Garcîa D, et al. Major histocompatibility complex and strong human leukocyte antigen – DRB1 and gender association with Vogt – Koyanagi – Harada syndrome in Mexican Mestizos. 2011;72:1198–203.
(5) Cantor LB, Rapuano CJ, Cioffi GA, Read RW, Acharya N, Levinson R. Inflammation I. Intraocular Inflammation and Uveitis. 2018; 71-100
(6) Shi T, Lv W, Zhang L, Chen J, Chen H. Association of hla-dr4/hla- drb104 with vogt-koyanagi-harada disease: A systematic review and meta-analysis. Sci Rep. 2014;4:1–8.
(7) Menezo V, Taylor SRJ. Role of HLA-DRB1 * 04 in Malay patients with Vogt-Koyanagi- Harada syndrome. 2019;82–3.
(8) Sukavatcharin S, Tsai JH, Rao NA. Vogt-Koyanagi-Harada disease in hispanic patients. Int Ophthalmol. 2007;27(2–3):143–8.
(9) Singhal N, Singh G. International journal of scientific research the clinical spectrum of vogt-koyanagi- harada syndrome in a tertiary Pathology ABSTRACT. 2019;(3):40–2.
(10) Iqniebi A, Gaafar A, Sheereen A, Al-Suliman A, Mohamed G, Al- Hussein K, et al. HLA-DRB1 among patients with Vogt-Koyanagi- Harada disease in Saudi Arabia. Mol Vis. 2009;15:1876–80.
(11) Vogt B, Society A, Aus T, Workshop VKHI. ScienceDirect “ Revised diagnostic criteria ” for Vogt-Koyanagi-Harada disease fail to impro- ve disease management. 2019;31:1–7.
(12) Lavezzo MM, Sakata VM, Morita C, Ernesto E, Rodriguez C, Abdallah SF, et al. Vogt-Koyanagi-Harada disease : review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis [Internet]. 2016;1–21. Available from: http:// dx.doi.org/10.1186/s13023-016-0412-4.
(13) Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2017;95(1):85–90.
(14) Yang P, Zhong Y, Du L, Chi W, Chen L, Zhang R, et al. Development and evaluation of diagnostic criteria for vogt-koyanagi-harada disease. JAMA Ophthalmol. 2018;136(9):1025–31.
(15) No Title1. Fisher, R. A. (1922). «On the interpretation of χ2 from contingency tables, and the calculation of P». Journal of the Royal Statistical Society 85 (1): 87-94. JSTOR 2340521. doi:10.2307/2340521.
(16) Fisher, R.A. (1954). Statistical Methods for Research Workers. Oliver and Boyd. ISBN 0-05-002170-2.
(17) Agresti, Alan (1992). «A Survey of Exact Inference for Contin- gency Tables». Statistical Science 7 (1): 131-153. JSTOR 2246001. doi:10.1214/ss/1177011454.
(18) Chee SP, Jap A, Bacsal K. Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol. 2007;27(2–3):137–42.
(19) Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical Charac- teristics of Vogt-Koyanagi-Harada Syndrome in Chinese Patients. Ophthalmology. 2007;114(3).
(20) Concha-del Río LE, Gómez L, Arellanes-García L. Corticothe- rapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease. Arch Soc Esp Oftalmol [Internet]. 2018;93(5):225–30. Available from: https://doi. org/10.1016/j.oftal.2017.09.010
(21) Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt- Koyanagi-Harada’s disease by PCR-RFLP and the strong associa- tion with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78(3):223–6.
(22) Weisz JM, Holland GN, Roer LN, Park MS, Yuge AJ, Moorthy RS, et al. Association between Vogt-Koyanagi-Harada Syndrome and HLA-DR1 and -DR4 in Hispanic Patients Living in Southern California. Ophthalmology [Internet]. 1995;102(7):1012–5. Available from: http://dx.doi.org/10.1016/S0161-6420(95)30920-7
(23) Arellanes-García L, Bautista N, Mora P, Ortega-Larrocea G, Burguet A, Gorodezky C. HLA-DR is strongly associated with Vogt-Koyanagi- Harada disease in Mexican Mestizo patients. Ocul Immunol Inflamm. 1998;6(2):93–100.
(24) Levinson RD, See RF, Rajalingam R, Reed EF, Park MS, Rao NA, et al. HLA-DRB1 and -DQB1 alleles in mestizo patients with Vogt- Koyanagi-Harada’s disease in Southern California. Hum Immunol. 2004;65(12):1477–82.